Mette Line R.
- Country
- Denmark
- Department
- Department of Pediatrics
Research Overview
- Phase III Study on Immunogenicity and Safety of MenACYW Conjugate Vaccine Versus Nimenrix in Healthy Infants and Toddlers
- Evaluation of Immunogenicity and Safety of GSKVX000000025896 Compared to Varicella Virus Oka/Merck Strain in Healthy Pediatric Subjects
- Evaluation of Immunogenicity and Safety of Intramuscular GSKVX000000025896 and Priorix Versus Subcutaneous Varicella Virus Oka/Merck Strain in Healthy Children Aged 12-15 Months
Data & Insights
Has run more than one trial at 10 of 63 partner sites.
Specializations
Vaccine Development
The investigator specializes in studying meningococcal conjugate vaccines, with particular focus on preventive immunization strategies for infants and toddlers.
- Meningococcal Serogroups A, C, W, and Y
- Pediatric Immunization
- Conjugate Vaccine Technology
Research activities center on evaluating immune responses in healthy young children.
Pediatric Medicine
Focused on preventive healthcare for specific age groups, particularly infants aged 6-7 months and toddlers aged 12-13 months.
- Infant Immunology
- Early Childhood Vaccination
- Age-Specific Immune Response
Expertise in evaluating medical interventions for young pediatric populations.
Immunology
Investigates immunogenicity patterns and protective responses in developing immune systems.
- Vaccine Safety Assessment
- Antibody Response Evaluation
- Geometric Mean Titers Analysis
Specializes in comparative immunological studies in pediatric populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.